LabPad is a portable in vitro diagnostic system that can be used to complete a wide variety of biological analyses. It is made up of a single reader and a broad range of consumable microcuvettes.
Avalun's LabPad is used in much the same way as a blood sugar test kit. The type of microcuvette selected determines which test will be carried out on a capillary (finger prick) blood sample.
The product aligns closely with the growing trend towards e-healthcare, offering communications capabilities to facilitate the exchange of information between the patient, the professional doing the test, and caregivers.
LabPad is the result of a good match between an enabling technology and a market need. The point-of-care market is steadily moving toward in-home care and patient-connected solutions. The trend is fueled by the multi-measurement systems being developed by startups spun off from world-class research institutions (UCLA, MIT, EPFL). Avalun's founders are developing technologies that enable all biological measurements and that are simple to integrate into patient care protocols.
For LabPad to reach its full potential, the company must rapidly get a broad range of measurements to market. And progress is well underway, supported by strong R&D programs like the French Single Interministerial Fund-backed DDIVA project, which Avalun won with the assistance of Minalogic.